FHI Clinical collaborating with Tactical Therapeutics, Inc., to refine the protocol for the development of carboxyamidotriazole orotate (CTO) to treat respiratory diseases

December 21, 2022 FHI Clinical is contributing to the protocol design for a Phase 2 clinical trial to evaluate carboxyamidotriazole orotate (CTO), an asset from Tactical Therapeutics.

Continue ReadingFHI Clinical collaborating with Tactical Therapeutics, Inc., to refine the protocol for the development of carboxyamidotriazole orotate (CTO) to treat respiratory diseases

Partner with FHI Clinical to confidently conduct high-quality research in sub-Saharan Africa

October 12, 2022 FHI Clinical Inc. is showcasing sub-Saharan Africa as a clinical trial destination through its 8-week FHI Clinical Africa campaign, culminating in a celebration at World Vaccine Congress Europe of the region’s rich cultural heritage and growing target as a hub for global clinical trials.

Continue ReadingPartner with FHI Clinical to confidently conduct high-quality research in sub-Saharan Africa

Evaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

September 7, 2022 The global ACTT-4 study, supported by FHI Clinical, evaluated baricitinib vs dexamethasone for adults hospitalized with COVID-19. This trial is the fourth and final stage in a series of phase 3, randomized, double-blind, placebo-controlled trials to evaluate the clinical efficacy and safety of investigational therapeutic agents in hospitalized adults with laboratory-confirmed COVID-19.

Continue ReadingEvaluation of baricitinib versus dexamethasone for adults hospitalized with COVID-19 in the global ACTT-4 study

FHI Clinical to write clinical trial protocol for development of Gb Sciences’ COVID-19-related anti-inflammatory therapies

May 2, 2022 FHI Clinical Inc. announces today it will consult on the go-to-market strategy for COVID-19 related anti-inflammatory therapeutics for Gb Sciences. FHI Clinical will additionally write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations.

Continue ReadingFHI Clinical to write clinical trial protocol for development of Gb Sciences’ COVID-19-related anti-inflammatory therapies

FHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

February 8, 2022 FHI Clinical Inc. announces today the official closing of its acquisition of the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD), a full-service, South Africa-based CRO. With the acquisition, FHI Clinical expands its share of the infectious disease (ID) clinical development market and becomes the dominant service provider in sub-Saharan Africa.

Continue ReadingFHI Clinical announces the closing of its acquisition of the clinical trials business of South Africa-based Triclinium Clinical Development (TCD)

FHI Clinical announces intent to acquire South African-based Triclinium Clinical Development (TCD)

December 2, 2021 FHI Clinical announces its intent to acquire TCD Global, a South African-based CRO. The acquisition allows FHI Clinical to expand its share of the infectious disease (ID) clinical development market and become the dominant service provider in sub-Saharan Africa.

Continue ReadingFHI Clinical announces intent to acquire South African-based Triclinium Clinical Development (TCD)

Evaluation of early warning systems for clinical assessment of patients with COVID-19 in the global study, ACTT-1

September 21, 2021 The results from this study provide important information about the clinical management of hospitalized patients with COVID-19. Additional research is needed to identify a method that can be used to accurately prioritize patients with COVID-19 at risk of critical illness or death.

Continue ReadingEvaluation of early warning systems for clinical assessment of patients with COVID-19 in the global study, ACTT-1

Tiziana and FHI Clinical enter a collaboration agreement for a phase 2 clinical trial of intranasal Foralumab to treat hospitalized patients with severe COVID-19

June 23, 2021 Tiziana and FHI Clinical announce collaboration on a Phase 2 study in Brazil to evaluate the safety, tolerability and efficacy of intranasal Foralumab in hospitalized patients with severe COVID-19 and pulmonary inflammation.

Continue ReadingTiziana and FHI Clinical enter a collaboration agreement for a phase 2 clinical trial of intranasal Foralumab to treat hospitalized patients with severe COVID-19

Baricitinib + remdesivir superior to remdesivir alone for hospitalized adults with COVID-19: ACTT-2 results published in NEJM

April 24, 2021 Results of the Adaptive COVID-19 Treatment Trial (ACTT)-2 investigating combination treatment with baricitinib, a Janus kinase inhibitor, and remdesivir for the treatment of COVID-19 in hospitalized adults were published in the New England Journal of Medicine (NEJM) on March 4, 2021, showing that the combination treatment was superior to remdesivir alone.

Continue ReadingBaricitinib + remdesivir superior to remdesivir alone for hospitalized adults with COVID-19: ACTT-2 results published in NEJM